Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
9p13.3 | Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 | 167320 | AD | 3 | VCP | 601023 |
Location | Phenotype | Inheritance |
Phenotype mapping key |
Phenotype MIM number |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
7p15.2 | ?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 | AD | 3 | 615422 | HNRNPA2B1 | 600124 |
9p13.3 | Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 | AD | 3 | 167320 | VCP | 601023 |
12q13.13 | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3 | AD | 3 | 615424 | HNRNPA1 | 164017 |
|
|
|
|
|
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
7p15.2 | ?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 | 615422 | AD | 3 | HNRNPA2B1 | 600124 |
Location | Phenotype | Inheritance |
Phenotype mapping key |
Phenotype MIM number |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
7p15.2 | ?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 | AD | 3 | 615422 | HNRNPA2B1 | 600124 |
9p13.3 | Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 | AD | 3 | 167320 | VCP | 601023 |
12q13.13 | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3 | AD | 3 | 615424 | HNRNPA1 | 164017 |
|
|
|
|
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
12q13.13 | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3 | 615424 | AD | 3 | HNRNPA1 | 164017 |
Location | Phenotype | Inheritance |
Phenotype mapping key |
Phenotype MIM number |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
7p15.2 | ?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 | AD | 3 | 615422 | HNRNPA2B1 | 600124 |
9p13.3 | Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 | AD | 3 | 167320 | VCP | 601023 |
12q13.13 | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3 | AD | 3 | 615424 | HNRNPA1 | 164017 |
|
|
|
|
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
12q13.13 | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3 | 615424 | AD | 3 |
?Myopathy, distal, 3 | 610099 | AD | 3 | |
Amyotrophic lateral sclerosis 20 | 615426 | AD | 3 |
|
|
|
|
|
|
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
7p15.2 | ?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 | 615422 | AD | 3 |
Oculopharyngeal muscular dystrophy 2 | 620460 | AD | 3 |
|
|
|
|
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
9p13.3 | Charcot-Marie-Tooth disease, type 2Y | 616687 | AD | 3 |
Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 | 613954 | AD | 3 | |
Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 | 167320 | AD | 3 |
|
|
|
|
|
|
|
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM